Dyne Therapeutics, Inc. (DYN) earnings
DYN earnings moved a median of -0.31% by the close. Quarterly and annual DYN reports and results, each read against the price at its own news timestamp. Back to the DYN overview →
21 measured DYN earnings events.
Where these DYN earnings landedvs 19 measured DYN earnings reactions
| Middle 50% of DYN earnings reactions | -5.17% to +5.07% |
|---|---|
| Median reaction (to close) | -0.31% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 DYN earnings events with a measured close landed between -5.17% and +5.07%; 42% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights | Press release | -3.14% | -7.56% | |
| Form 10-Q Dyne Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -3.14% | -7.56% | |
| Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Press release | +1.14% | +5.02% | |
| Form 10-Q Dyne Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.14% | +5.02% | |
| Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | Press release | +3.33% | +5.13% | |
| Form 10-Q Dyne Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +3.33% | +5.13% | |
| Form 10-K Dyne Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +2.30% | +9.27% | |
| Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Press release | -5.75% | -13.56% | |
| Form 10-Q Dyne Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -5.75% | -13.56% | |
| Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | Press release | -0.68% | — | |
| Form 10-Q Dyne Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.68% | — | |
| Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | Press release | +1.98% | +17.90% | |
| Form 10-Q Dyne Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.98% | +17.90% | |
| Form 10-K Dyne Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.51% | -3.87% | |
| Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | +3.78% | +4.60% | |
| Form 10-Q Dyne Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +2.85% | -2.78% | |
| Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | Press release | -3.37% | -1.36% | |
| Form 10-Q Dyne Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -3.37% | -1.36% | |
| Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | Press release | +2.14% | -0.31% | |
| Form 10-Q Dyne Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +2.14% | -0.31% | |
| Form 10-K Dyne Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.76% | -6.47% |
Keep exploring
More DYN: analyst actions → · SEC filings → · DYN overview →